ABVIDA M 50/500MG TAB

Distributor inventory | Tablet

Type 2 diabetes mellitus—adjunct to diet and exercise to improve glycaemic control in adults, especially when metformin alone is inadequate

Vildagliptin is a DPP-4 inhibitor that increases incretin hormones (GLP-1, GIP), enhancing glucose-dependent insulin release and reducing glucagon. Metformin reduces hepatic glucose production and improves insulin sensitivity, lowering blood glucose without usually causing hypoglycaemia when used alone.

Oral tablet. Take exactly as prescribed, typically with meals to reduce stomach upset. Swallow whole with water (do not crush/chew if it is an SR/ER tablet). Dose is individualized based on kidney function and blood sugar; continue diet and exercise.

Nausea, vomiting, diarrhoea, abdominal pain, loss of appetite, metallic taste, headache, dizziness, tremor, upper respiratory tract infection, hypoglycaemia (more likely with other antidiabetics), increased liver enzymes

Contraindicated in severe renal impairment; assess eGFR before starting and periodically. Risk of lactic acidosis with metformin (higher risk in renal/hepatic impairment, dehydration, severe infection, hypoxia, excessive alcohol use); stop and seek urgent care if unexplained muscle pain, fast breathing, severe weakness, or abdominal discomfort occur. Vildagliptin may cause hepatitis; check LFTs at baseline and during therapy and stop if jaundice or persistent ALT/AST elevation. Use caution in heart failure and in elderly. Temporarily discontinue metformin before iodinated contrast procedures and major surgery as advised by doctor.